Austin Hewlett, PharmD-MBA Candidate
The FDA recently approved Ingrezza (valbenazine) for the treatment of adults with tardive dyskinesia.
Two of the biggest players in the retail pharmacy market are expected to merge this year. What does that mean for patients, pharmacists, and investors?
Gilead Sciences maker of hepatitis C virus blockbusters Sovaldi, Harvoni, and, most recently, Epclusa has come under increasing scrutiny for declining revenues, both in the near-term and beyond.
With the advancing landscape of digital health technology, medication compliance may no longer be a hard pill to swallow.
Several biologic drug manufacturers face biosimilar competition, but are financial markets pricing them appropriately?
The Federal Government offers several loan forgiveness options, some of which may apply to pharmacists. Read to see if there is an option that could benefit you.
+ Load More